(PRTA) Prothena - Ratings and Ratios

Prothena Corporation plc, a late-stage clinical biotechnology company, is dedicated to advancing therapies that address diseases caused by protein dysregulation. Established in 2012 and headquartered in Dublin, Ireland, Prothena employs a precision medicine approach to target specific proteinopathies, focusing on neurodegenerative and amyloid diseases. Their pipeline includes several promising candidates, each at various stages of development.

Leading their pipeline is birtamimab, an antibody in Phase III trials for AL amyloidosis, a condition where abnormal protein deposits damage vital organs. Prasinezumab, in Phase IIb, targets synucleinopathies such as Parkinsons disease and multiple system atrophy. Additionally, NNC6019 is in Phase II for ATTR amyloidosis, addressing both hereditary and wild-type forms. Their early-stage assets include BMS-986446, a tau-targeting antibody for Alzheimers, and PRX012, a bispecific antibody also for Alzheimers, both in Phase I. Prothenas preclinical efforts feature PRX123, a dual Aβ-Tau vaccine for Alzheimers prevention, and PRX019 for neurodegenerative diseases, including ALS by targeting TDP-43.

Strategic collaborations enhance Prothenas capabilities. They partner with Roche on alpha-synuclein antibodies, including prasinezumab, and with Bristol-Myers Squib